JP2010516290A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516290A5
JP2010516290A5 JP2009548278A JP2009548278A JP2010516290A5 JP 2010516290 A5 JP2010516290 A5 JP 2010516290A5 JP 2009548278 A JP2009548278 A JP 2009548278A JP 2009548278 A JP2009548278 A JP 2009548278A JP 2010516290 A5 JP2010516290 A5 JP 2010516290A5
Authority
JP
Japan
Prior art keywords
regulatory
cell
cells
cell epitope
epitope polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548278A
Other languages
English (en)
Japanese (ja)
Other versions
JP4866467B2 (ja
JP2010516290A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001148 external-priority patent/WO2008094538A2/en
Publication of JP2010516290A publication Critical patent/JP2010516290A/ja
Publication of JP2010516290A5 publication Critical patent/JP2010516290A5/ja
Application granted granted Critical
Publication of JP4866467B2 publication Critical patent/JP4866467B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548278A 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用 Expired - Fee Related JP4866467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89834707P 2007-01-30 2007-01-30
US60/898,347 2007-01-30
PCT/US2008/001148 WO2008094538A2 (en) 2007-01-30 2008-01-29 Regulatory t cell epitopes, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011247226A Division JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2010516290A JP2010516290A (ja) 2010-05-20
JP2010516290A5 true JP2010516290A5 (enExample) 2011-06-16
JP4866467B2 JP4866467B2 (ja) 2012-02-01

Family

ID=39674696

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2009548278A Expired - Fee Related JP4866467B2 (ja) 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用
JP2014154372A Expired - Fee Related JP6121369B2 (ja) 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用
JP2014154372A Expired - Fee Related JP6121369B2 (ja) 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Country Status (11)

Country Link
US (18) US7884184B2 (enExample)
EP (13) EP2423222B2 (enExample)
JP (10) JP4866467B2 (enExample)
KR (3) KR101722305B1 (enExample)
CN (4) CN107011431B (enExample)
AT (1) ATE525392T1 (enExample)
AU (1) AU2008211227B2 (enExample)
CA (6) CA3161849A1 (enExample)
IL (3) IL200129A (enExample)
MX (3) MX347197B (enExample)
WO (1) WO2008094538A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN106986927A (zh) * 2011-12-13 2017-07-28 法国国家科学研究中心 修饰肽及其用于治疗自体免疫疾病的用途
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
CA3177878A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
CN107427590B (zh) 2015-02-02 2021-08-31 伯明翰大学 具有多个t细胞表位的靶向部分肽表位复合物
MX2017014146A (es) 2015-05-04 2018-08-14 Epivax Inc Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7.
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
PL3377103T5 (pl) 2015-11-19 2025-07-07 Revitope Limited Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
AU2018346681B2 (en) 2017-10-05 2024-02-22 Epivax, Inc. Regulatory T cell epitopes
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
CA3138867A1 (en) * 2019-05-03 2020-11-12 Guilhem RICHARD Neoantigens in cancer
KR20220160023A (ko) * 2020-03-27 2022-12-05 바이오테스트 아게 조절성 t 세포를 활성화하는 하나 이상의 에피토프를 포함하는 단백질
CA3172976A1 (en) * 2020-03-27 2021-09-30 Epivax, Inc. Regulatory t cell epitopes
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
EP4196232A2 (en) * 2020-08-13 2023-06-21 Epivax, Inc. Regulatory t cell epitopes
CA3193819A1 (en) * 2020-09-25 2022-03-31 Anne De Groot Retro-inverso regulatory t cell epitopes
IL310143A (en) * 2021-07-16 2024-03-01 Dbv Tech An immunotherapeutic method to increase resistance to cashew in the patient
WO2024240690A2 (en) 2023-05-19 2024-11-28 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO1997034632A1 (en) 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
EP1007569B1 (en) * 1997-02-11 2009-04-08 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
EP0979102A4 (en) * 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6445840B1 (en) 1999-05-28 2002-09-03 Omm, Inc. Micromachined optical switching devices
DE60040147D1 (de) 1999-05-28 2008-10-16 Targeted Genetics Corp Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002005146A2 (en) 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR20050044405A (ko) * 2001-11-12 2005-05-12 메르크 파텐트 게엠베하 변형된 항-ｔｎｆ 알파 항체
CA2469078A1 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
ZA200406124B (en) 2002-02-07 2008-09-25 Delta Biotechnology Ltd Albumin-fused kunitz domain peptides
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1532262T3 (da) 2002-05-24 2013-09-16 Medtronic Inc Peptidamideringsfremgangsmåde
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CN1511958A (zh) * 2002-12-31 2004-07-14 王小宁 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2005035575A2 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
KR101332927B1 (ko) 2004-02-06 2013-11-26 메다렉스, 인코포레이티드 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
DK1729795T3 (en) 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
ES2424643T3 (es) * 2004-03-19 2013-10-07 Merck Patent Gmbh Proteínas bouganina modificadas, citotoxinas y procedimientos y usos de las mismas
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
SG161242A1 (en) 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
JP2008528668A (ja) * 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
CN100349921C (zh) * 2005-11-17 2007-11-21 中国人民解放军第四军医大学 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
JP5096369B2 (ja) * 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
AT503861B1 (de) † 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CA3161849A1 (en) * 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
JP2010528664A (ja) 2007-06-08 2010-08-26 ダウ グローバル テクノロジーズ インコーポレイティド Ｃｈ１ドメインの切断による可溶性抗体断片の発現

Similar Documents

Publication Publication Date Title
JP2010516290A5 (enExample)
CN107148427B (zh) 新型免疫原性肽
JP6484293B2 (ja) Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
JP2015521467A5 (enExample)
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
De Amicis et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes
JP2008529558A5 (enExample)
KR20220132023A (ko) 신규 면역원성 CD1d 결합 펩티드
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
JP2006506942A5 (enExample)
JP2010535504A5 (enExample)
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
CN101455846B (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
CN103596971A (zh) 通过删除由nkt细胞识别的表位来调整抗原免疫原性
US12414987B2 (en) Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof
WO2018049130A1 (en) Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases
EP1668036A2 (fr) Procede a haut rendement pour l' obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2017177910A1 (zh) 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
EP3574915A1 (en) Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
CN115916805A (zh) 具有延伸的氧化还原酶基序的免疫原性肽
CA2795308A1 (en) Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
US20240148864A1 (en) Polysaccharide adjuvants for virus vaccines
US20230218741A1 (en) Sars-cov-2 vaccines for population-scale immunity
KR20240015672A (ko) 면역원성 펩티드를 사용한 개선된 치료 방법